Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1702287

registered interest
date	18/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breastfeeding
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential impact of increased rates of breastfeeding on cost savings for the NHS.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	22611
answer	answer is ministerial correction date of answer 25/04/2024 answer text <p>The public health benefits of breastfeeding for child and maternal health are significant and well established. Research published in the British Medical Journal suggests that increasing breastfeeding rates, both in terms of duration and exclusivity, is likely to generate substantial cost savings to the National Health Service, although the actual amounts saved will depend on the extent of this increase.</p><p>Through the Family Hubs and Start for Life Programme, we are investing £50 million to increase the range of specialist support, which is enabling more parents to access face-to-face and virtual support whenever they need it. One of the objectives of the programme is to improve the evidence base around the impact of breastfeeding interventions, and the specific combination of interventions that are effective in different circumstances. This is expected to strengthen the case for further, more widespread investment in the future.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 25/04/2024 11:32:06 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4623 label Biography information for Tonia Antoniazzi

1689180

registered interest
date	16/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Shortages
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what comparative assessment she has made of trends in the total number of medicine shortages recorded by her Department in January (a) 2021, (b) 2022, (c) 2023 and (d) 2024.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	14113
answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>There are around 14,000 licensed medicines, and the overwhelming majority are in good supply. However, the medicine supply chain is highly regulated, complex and global, and supply disruption is a common issue which affects countries all around the world.</p><p>The Department’s medicine Discontinuations and Shortages portal has been collecting notifications from suppliers of potential supply issues since October 2020, and shows that there were approximately:</p><p>- 90 supply issue notifications in January 2021;</p><p>- 110 supply issue notifications in January 2022;</p><p>- 170 supply issue notifications in January 2023; and</p><p>- 160 supply issue notifications in January 2024.</p><p>Although reporting does vary each month, annual notifications have remained fairly stable at approximately 1,600 supply issue notifications in 2022 and 2023. It is important to note that not all supply issue notifications will lead to a medicine shortage.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/02/2024 11:24:53 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4623 label Biography information for Tonia Antoniazzi

1689181

registered interest
date	16/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with the Medicines and Healthcare products Regulatory Agency on the average licensing approval decision timelines for (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	14114
answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.</p><p>We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14115 question first answered 27/02/2024 11:32:52 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4623 label Biography information for Tonia Antoniazzi

1689182

registered interest
date	16/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps with the Medicines and Healthcare products Regulatory Agency to reduce the time taken to license (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	14115
answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.</p><p>We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14114 question first answered 27/02/2024 11:32:52 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4623 label Biography information for Tonia Antoniazzi